Phycotransgenics, LLC

PHYCOTRANSGENICS, LLC, 3416 ASHWOOD DR
Bloomington, IN 47401

SBIR Award Summary

Total Number of Awards 6
Total Value of Awards $525K
First Award Date 01/01/01
Most Recent Award Date 08/01/04

Key Personnel

Last Name Name Awards Contact
Wagner Richard E. Wagner 6 Message

6 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/04 - 01/31/06

DESCRIPTION (provided by applicant): The commercial goal of Phycotransgenics, L.L.C. is to develop economical and effective oral vaccine for animals and humans. The specific aim of this proposal is the development of a microalgal-based oral vaccine for the prevention of amebic dysentery in humans caused by the protozoan parasite Entamoeba histol...

Phase 1 SBIR

Agency: Department of Agriculture
Topic: 2003
Budget: 01/01/03 - 12/31/03

NON-TECHNICAL SUMMARY: The impetus to raise wholesome food products with limited use of antimicrobial agents has provided new challenges to poultry producers. Intensive production is a main feature that contributes to the productivity and efficiency of the poultry industry. A consequence of intensive production is the increased risk of the sprea...

Phase 1 SBIR

Agency: Department of Commerce
Topic: 2002
Budget: 01/01/02 - 12/31/02

Phycotransgenics goal is to develop a vaccine delivery system using microalgae to reduce diseaseassociated costs for aquaculture. To accomplish this, we transformed Chlamydomonas, a single-cell algal species, with an antigen gene. Through our Phase 1 Program, we demonstrated that: 1) an antigen expressed in our algae can elicit an immune respons...

Phase 2 SBIR

Agency: Department of Commerce
Topic: 2002
Budget: 01/01/02 - 12/31/02
PI: Unavailable

Phycotransgenics goal is to develop a vaccine delivery system using microalgae to reduce diseaseassociated costs for aquaculture. To accomplish this, we transformed Chlamydomonas, a single-cell algal species, with an antigen gene. Through our Phase 1 Program, we demonstrated that: 1) an antigen expressed in our algae can elicit an immune respons...

Phase 1 SBIR

Agency: National Science Foundation
Topic: 2002
Budget: 01/01/02 - 12/31/02

This Small Business Innovation Research (SBIR) Phase I project will develop oral vaccines for controlling white spot syndrome virus (WSSV)in marine shrimp using transgenic algae. In recent years shrimp production on Latin American shrimp farms has been reduced by up to 50 percent by WSSV outbreaks. Current technologies for controlling WSSV have ...

Phase 1 SBIR

Agency: Department of Commerce
Topic: 2001
Budget: 01/01/01 - 12/31/01